91¹ú²ú¾«Æ·

Jump to Main Content

Meetings

ASH Summit on Immunotherapies for Hematologic Diseases

March 2-3, 2023
Omni Shoreham Hotel, Washington, DC

Why is the success of immunotherapies and other targeted therapies such as gene therapy so variable within different patient populations? How can we improve these targeted therapies for widespread use in patients with hematologic diseases? Help answer these questions and more at the ASH Summit on Immunotherapies for Hematologic Diseases.

This in-person Summit is a unique meeting of the minds, bringing together  academic, medical, industry, and federal regulatory communities to address the obstacles in immunotherapy treatment development for classical and malignant hematologic conditions. Whether you’re an established academic investigator, trainee, practicing clinician, industry researcher, or federal regulator, you won’t want to miss this unique opportunity to share ideas! Through participation in this meeting, attendees will be able to: 

  • Discuss fundamental advances in basic immunology that provide the foundation for immune therapies and their application
  • Gain insights into critical limitations of immunotherapies and gene therapy including associated adverse events
  • Examine cellular and molecular mechanisms involved in resistance and relapse associated with these therapies
  • Review new immunotherapy targets
  • Discuss the application of CRISPR gene editing in the development of targeted therapies
  • Analyze cell manufacturing considerations
  • Learn about the application of immunotherapies for the treatment of both classical hematologic and malignant diseases

Target Audience

The ASH Summit on Immunotherapies for Hematologic Diseases is designed to provide a wide set of learning and networking opportunities for experts in hematology, including:

  • Laboratory-based scientists
  • Translational and clinical researchers
  • Practitioners interested in the application of immunotherapies
  • Young investigators (trainees)
  • Cellular therapy, gene therapy, biopharmaceutical, and life sciences industry experts
  • Regulatory scientists

View abstract categories

Summit Abstracts

Full abstract text will be available to registered attendees via the mobile app. In accordance with the event’s embargo guidelines, for poster presentations, the embargo lifts when the poster hall containing the poster opens for viewing and for oral/invited presentations, the embargo lifts at the start time of the session in which the presentation is being made.

 Abstract #  Title  Presenter  Presentation
1 HMGA1 Chromatin Regulators Drive Immune Evasion in MPN Progression through Epigenetic Rewiring to Repress Networks Involved in Antigen Presentation Joseph Kim Oral
2 Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial Swati Naik Oral
3 Tgfß-Imprinting of Primary NK Cells Decreases CD38-Nadase, Promotes a Tissue-Resident Addressin Profile, and Improves Cytotoxicity and Metabolism Marcelo Pereira Oral
4 Rhoa Inactivation As a Driver of CAR-T Therapy Resistance in Diffuse Large B-Cell Lymphoma Austin D. Newsam Oral
5 Tunable Activation of CD19-CART Results in Enhanced Metabolic Activity and Cytotoxicity Against Antigen-Low Leukemia Mehdi Benzaoui Oral
6 Evaluation of CD38KO/CD38-CAR Human Primary Natural Killer Cells Against CD38-Expressing Hematologic Malignancies Ella C. Troy Oral
LBA - 1 Cord Blood-Derived CD19-Specific Chimeric Antigen Receptor T Cells: An Off-the-Shelf Promising Therapeutic Option for Treatment of Diffuse Large B-Cell Lymphoma Tiantian Yu Oral
7 Deletion of AMPK Reduces Oxidative Metabolism in Gvhd-Causing Human T Cells Archana Ramgopal Poster & Rapid Fire Talk
8 Novel Therapeutic Strategies to Overcome Hyperthermia-Induced Metabolic Dysfunction of CAR-T Cells Taisuke Kondo Poster & Rapid Fire Talk
9 Use of a Foamy-Virus Vector System to Produce an ‘Off-the-Shelf’ Fcγ-CR-T Cell Product for the Treatment of Hematological and Solid Tumor Malignancies Ioanna Lazana Poster & Rapid Fire Talk
10 Multiple Myeloma & Severe Sars-Cov-2: Delving into the Immunological Paradigm with a Promising Cellular Therapeutic Intervention Yan Leyfman Poster
11 The Roles and Challenges of Advanced Therapies in the Management of Refractory Immune Thrombocytopenia: A Case Report and Review of Literature Beatrice Torere Poster
12 Correlations between Overall Response Rate, Progression-Free Survival and Overall Survival with Belantamab Mafodotin in Refractory or Relapsed Multiple Myeloma Nosakhare Ilerhunmwuwa Poster
13 A Retrospective Study of Clinical Outcomes in Patients with Non-Hodgkin Lymphoma with Secondary Central Nervous System Involvement after CD19 CAR-T Therapy Aseel Alsouqi Poster & Rapid Fire Talk
14 Longitudinal Geriatric Assessment in Older Patients with Relapsed Refractory, Large B-Cell Lymphoma Receiving CAR T-Cell Therapy: A Prospective Pilot Study Richard Lin Poster & Rapid Fire Talk
15 Hemophagocytic Lymphohistiocytosis As a Complication of CAR-T Cell Therapy: A Case Report Flavia Gava Poster
16 Outcomes of Myeloid Sarcoma: A 10-Year Institutional Study Kriti Gera Poster
17 Visualizing CAR-T Cell Trafficking Using the NIS Reporter Brynn Duncan Poster & Rapid Fire Talk
18 Bridging the Gap of Healthcare Access: Utilizing an Ontology Platform to Connect BALT Patients with COVID-19 to Active Immunotherapeutic Clinical Trials Yan Leyfman Poster
19 Viral Escape in Cytomegalovirus Viral-Specific T Cell Therapy Resistance John Idso Poster
LBA-2 The CLEC2D/CD161 Axis As a Novel Ligand/Receptor Pathway for Immunotherapeutic Intervention in CLEC2D+Hematological Malignancies Shruti Malu Poster

Abstract Winners

Joseph Kim
Johns Hopkins University School of Medicine
HMGA1 Chromatin Regulators Drive Immune Evasion in MPN Progression through Epigenetic Rewiring to Repress Networks Involved in Antigen Presentation

Brynn B. Duncan, MD
National Heart, Lung, and Blood Institute, National Institutes of Health

Visualizing CAR-T Cell Trafficking Using the NIS Reporter
Austin D. Newsam, BS
University of Miami Miller School of Medicine
Rhoa Inactivation As a Driver of CAR-T Therapy Resistance in Diffuse Large B-Cell Lymphoma
Taisuke Kondo, PhD
National Institutes of Health
Novel Therapeutic Strategies to Overcome Hyperthermia-Induced Metabolic Dysfunction of CAR-T Cells
Aseel Alsouqi, MD
University of Pittsburgh Medical Center
A Retrospective Study of Clinical Outcomes in Patients with Non-Hodgkin Lymphoma with Secondary Central Nervous System Involvement after CD19 CAR-T Therapy

Program Schedule

7:00 a.m.
Hampton Ballroom
Breakfast/Exhibits Open

8:15 a.m.
Blue Room

Keynote Address

Chair:
Shannon Maude, MD, PhD
University of Pennsylvania
Philadelphia, PA

Speaker:
T cell Therapies for Patients with Blood Disorders: Broadening Applicability
Catherine Bollard, MD, MBChB
Children's National Hospital
Washington, DC

9:00 a.m.
Blue Room

The Science of Immunotherapy

Chairs:

Antonio Risitano, MD, PhD
University of Naples
Naples, Italy

Madhav Dhodapkar, MBBS
Emory University
Atlanta, GA

Speakers:

Personalized Immune Based Strategies in Cancer
Catherine Wu, MD
Dana-Farber Cancer Institute
Boston, MA

The Future of Science of Cancer Immunotherapy
Ira Mellman, PhD
Genentech
New York, NY

Uncertain Mechanisms of Action of Successful Biologics - ATG Focus
Phillip Scheinberg, MD
Hospital A Beneficênica Portuguesa de São Paulo
São Paulo, Brazil

10:55 a.m.
Blue Room

Use of Immunotherapies in Clinical Practice or Trials

Chairs:

Katy Rezvani, MD
The University of Texas MD Anderson Cancer 
Houston, TX

Sarah Cooley, MD
Fate Therapeutics, Inc.
San Diego, CA

Speakers:

Chimeric Antigen Receptor (CAR) Engineering Beyond T-Cells 
Dean Lee, MD, PhD
The Research Institute At Nationwide Children’s Hospital
Columbus, OH

T-Cell Engineering Beyond CAR 
Aude Chapuis, MD
Fred Hutchinson Cancer Research Center
Boston, MA

12:00 p.m.
Hampton Ballroom
Lunch/Exhibits Open

1:00 p.m.
Blue Room

Use of Immunotherapies in Clinical Practice or Trials (Continued)

Chairs:

Katy Rezvani, MD
The University of Texas MD Anderson Cancer
Houston, TX

Sarah Cooley, MD
Fate Therapeutics, Inc.
San Diego, CA

Speakers:

Bispecific Antibodies in Hemophilia
Stacy Croteau, MD
Children's Hospital Boston
Boston, MA

Presentation from the Chinese Society of Hematology: BCMA CART in China and Beyond
Chengcheng Fu, MD, PhD
The First Affilliated Hospital of Soochow University
Suzhou, CHN

2:30 p.m.
Blue Room

Mechanisms of Resistance to Immunotherapies

Chairs:

Rodrigo Calado, MD, PhD
University of São Paulo
São Paulo, Brazil

Loretta Nastoupil, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Speakers:

Initial Treatment Failure
Robbie Majzner, MD
Stanford University
Stanford, CA

Relapse Associated with Late Immunotherapy Failure
Nirali Shah, MD
National Cancer Institute
Bethesda, MD

Targeting Innate Immunity: Anti-Complement Therapies
Eleni Gavriilaki, MD, PhD
George Papanicolaou General Hospital
Thessaloniki, Greece

4:55 p.m.
Blue Room

Cell Manufacturing Considerations: Transitioning from Early to Late Phase Trials to Licensure

Chairs:

Catherine Bollard, MD, MBChB
Children's National Hospital
Washington, DC

Terry Fry, MD
University of Colorado School of Medicine
Aurora, CO

Speakers:

Academia Perspective: Challenges in the Academia Setting to Take Novel Platforms into the Clinic - How Have They Approached IND Filings (gene editing)
Isabelle Riviere, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Industry Perspective: Challenges in the Industry Setting; Dealing with Adverse Events (from a GMP Perspective)
Gwen Binder, PhD
Cabaletta Bio
Philadelphia, PA

The Regulatory Perspective: Cell Manufacturing Considerations
Andrew Timmons, PhD
US Food and Drug Administration
Washington, DC

Tunable Activation of CD19-CART Results in Enhanced Metabolic Activity and Cytotoxicity Against Antigen-Low Leukemia
Mehdi Benzaoui
National Cancer Institute
Bethesda, MD

6:40 p.m.
Blue Pre-Function Room
Welcome Reception and Poster Presentations

8:00 a.m.
Hampton Ballroom

Breakfast/Exhibits Open

9:00 a.m.
Blue Room

Emerging Strategies to Overcome Current Immunotherapy Limitations 

Chairs:

David Scott, PhD
Uniformed Services University of Health Sciences
Bethesda, MD

Frederick Locke, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

Speakers:

Emicizumab and ITI: Partners or Foes
Shannon Meeks, MD, MBA
Emory University
Atlanta, GA

Improving CAR T By Promoting Intracellular and Extracellular Signaling
Marcela Maus, MD, PhD, Massachusetts General Hospital
Harvard Medical School
Boston, MA

Genome Editing for Adoptive T Cell Therapy
Chiara Bonini, MD
Ospedale San Raffaele
Milan, Italy

11:00 a.m.
Blue Pre-Function Room

Poster Presentations

12:00 p.m.
Hampton Ballroom

Lunch/Exhibits

1:00 p.m.
Blue Room

Immunotherapy Toxicities – Prediction and Management

Chairs:

Jae Park, MD
Memorial Sloan-Kettering Cancer
New York, NY

Rayne Rouce, MD
Clinical Care Center-Texas Children's Hospital
Houston, TX

Speakers:

Cytokine Release Syndrome
David Teachey, MD
Children's Hospital of Philadelphia
Philadelphia, PA

Neurotoxicity
Juliane Gust, MD, PhD
Seattle Children's Hospital
Seattle, WA

Off-Target Effects of Immunotherapy
Elad Sharon, MD, MPH
Cancer Therapy Evaluation Program
Bethesda, MD

2:55 p.m.
Blue Room

Late Breaking Special Session (ASH-SITC JOINT Session)

Chairs:

John Tisdale, MD
NIH Molecular & Clinical Hematology
Bethesda, MD

Nina Shah, MD
University of California San Diego
San Diego, CA

Speakers:

The Immune Predictors of Response to CAR T and Bispecific T Cell Therapy
Paola Neri, MD, PhD
University of Calgary
Calgary, Canada

Novel Technologies to Improve and Safely Deliver Gene Therapies
Jennifer E. Adair, PhD
Fred Hutchinson Cancer Center
Boston, MA

Cord Blood-Derived CD19-Specific Chimeric Antigen Receptor T Cells: An Off-the-Shelf Promising Therapeutic Option for Treatment of Diffuse Large B-Cell Lymphoma
Tiantian Yu, PhD
The Second Affiliated Hospital of Nanchang University
Nanchang, China

View the Schedule at-a-Glance for additional details on the Summit’s program.

2023 Program Co-Chairs

  • Shannon Maude, MD, PhD, Children’s Hospital of Philadelphia
  • Terry Fry, MD, University of Colorado School of Medicine and Sana Biotechnology
  • Neal Young, MD, National Institutes of Health

ASH Summit Steering Committee

  • Catherine Bollard, MD, Children’s National Medical Center 
  • Rodrigo Calado, MD, PhD, University of Sao Paulo 
  • Sarah Cooley, MD, MS, Fate Therapeutics 
  • Madhav Dhodapkar, MD, Emory University 
  • Stephen Forman, MD, City of Hope 
  • Frederick Locke, MD, Moffitt Cancer Center 
  • Loretta Nastoupil, MD, MD Anderson Cancer Center 
  • Jae Park, MD, Memorial Sloan Kettering Cancer Center 
  • Katy Rezvani, MD, PhD, Anderson Cancer Center 
  • Antonio Risitano, MD, PhD, University of Naples 
  • David Scott, MS, PhD, Uniformed Services University of Health Sciences 
  • Guy Young, MD, Children’s Hospital of Los Angeles 

Questions?

For questions about the program for the 2023 ASH Summit on Immunotherapies for Hematologic Diseases, please contact ASH Deputy Director of Scientific Affairs Alice Kuaban at [email protected].

For general inquiries about this meeting, please submit them to [email protected].